3646 results for «722»
3646 results
TAVI and aortic valve procedures
11 Oct 2025 – From AICT-AsiaPCR 2025
Focusing on transcatheter aortic valve interventions, this session covers a broad spectrum of complex cases including emergent TAV-in-SAV procedures, management of severely calcified bicuspid valves, zero-contrast TAVI techniques, and strategies for hostile anatomies. It provides valuable insights into procedural planning and follow-up to optimize patient care...
Valve-in-valve in degenerated surgical bioprothesis mitral valve - LIVE Case
10 Oct 2025 – From AICT-AsiaPCR 2025
A 78-year-old male with a history of rheumatic disease underwent surgical mitral valve replacement (Perimount Magna 25), surgical aortic valve replacement (Perimount Magna), and CABG (LIMA–LAD) in 2010. He presented with symptomatic severe mitral regurgitation and normal LV function.
He was treated with implantation of a 26...
IVUS or OCT? Choosing the right imaging for the right lesion - A case-based debate
10 Oct 2025 – From AICT-AsiaPCR 2025
This case-based debate examines the complementary roles of IVUS and OCT imaging modalities in precision PCI. It highlights lesion-specific factors guiding modality choice, including left main disease, bifurcations, calcified plaques, and acute coronary syndromes, supported by real-world clinical cases demonstrating imaging-based decision-making.
EuroPCR 2018 Opening Ceremony and Ethica Awards
22 May 2018 – From EuroPCR 2018
Join J. Fajadet and W. Wijns for the EuroPCR 2018 Opening Ceremony and find out who this year's Ethica Awards winners are!
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
